It is of particular interest as treatment with an activating (agonist) anti-OX-40 monoclonal antibody (mAb) augments T-cell differentiation and cytolytic function leads to enhanced anti-tumor immunity against a variety of tumors [11]. Here, TNFRSF4 is linked to neoplasm.